TY - JOUR T1 - Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis JF - Thorax JO - Thorax SP - 884 LP - 885 DO - 10.1136/thoraxjnl-2013-203765 VL - 68 IS - 9 AU - Ludmila Shulgina AU - Anthony P Cahn AU - Edwin R Chilvers AU - Helen Parfrey AU - Allan B Clark AU - Edward C F Wilson AU - Orion P Twentyman AU - Anthony G Davison AU - John J Curtin AU - Michael B Crawford AU - Andrew M Wilson Y1 - 2013/09/01 UR - http://thorax.bmj.com/content/68/9/884.abstract N2 - We thank Neto et al 1 for their comments on our paper2 and for reiterating the points contained within it. ‘The survival benefit conferred by co-trimoxazole, if real, could be due to its antimicrobial activity as there was a significant reduction in the number of infections in the group receiving active treatment’, and this is likely to occur more frequently in patients receiving immunosuppressive treatment. The proportion of deaths in the intention-to-treat group on immunosuppression was 29 of 37. As stated, ‘this study was not designed to collect microbiological information’ however, the results were adjusted for baseline azathioprine or mycophenylate … ER -